Zanubrutinib: all 149 studies that test it
Page 1 of 2. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.
- Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSLRecruitingNCT07839247Phase 2
- Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 TrialNot yet recruitingNCT07812246Phase 2
- A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell LymphomaNot yet recruitingNCT07799220Phase 2
- Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Not yet recruitingNCT07739459Phase 2
- Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingNCT07734038Phase 2
- Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell VariantEnrolling by invitationNCT07690761Phase 2
- A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic LeukemiaNot yet recruitingNCT07674810Phase 2
- A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL PatientsRecruitingNCT07671378Phase 2
- Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentNot yet recruitingNCT07638722Phase 2
- Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 SubtypesRecruitingNCT07608978Phase 2
- AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCLNot yet recruitingNCT07594899Phase 2
- Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaRecruitingNCT07418190Phase 2
- Zanubritnib and Anti-MAG NeuropathyRecruitingNCT07392229Phase 2
- Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell LymphomaRecruitingNCT07371923Phase 2
- Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell TherapyRecruitingNCT07341191Phase 2
- Optimal Dose of Zanubrutinib to Treat Adult Immune ThrombocytopeniaNot yet recruitingNCT07315373Phase 1
- Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular LymphomaRecruitingNCT07299149Phase 2
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingNCT07277231Phase 3
- Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaRecruitingNCT07270835Phase 4
- Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell LymphomaRecruitingNCT07261163Phase 2
- Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLRecruitingNCT07012980Phase 2
- Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center StudyNot yet recruitingNCT07003464Phase 2
- ZR-MTX for PIOL Phase II TrialRecruitingNCT06973811Phase 2
- Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's MacroglobulinemiaNot yet recruitingNCT06942507Not applicable
- Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06859008Phase 1
- Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLLRecruitingNCT06849713Phase 2
- Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+RecruitingNCT06846463Phase 2
- Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell LymphomaRecruitingNCT06839053Phase 2
- Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLRecruitingNCT06803693Phase 2
- Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's TransformationRecruitingNCT06735664Phase 1
- Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS LymphomaRecruitingNCT06730542Phase 1
- Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial RemissionNot yet recruitingNCT06669143Phase 2
- High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)Not yet recruitingNCT06646211Phase 2
- Epco, Zanu, Ritux for R/R FL or MZLRecruitingNCT06563596Phase 2
- A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT06563505Phase 2
- Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMRecruitingNCT06561347Phase 2
- Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell LymphomaRecruitingNCT06558604Phase 2
- A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT06554600Phase 2
- Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)Not yet recruitingNCT06549335Phase 2
- Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström MacroglobulinemiaNot yet recruitingNCT06547866Phase 2
- Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT06544785Phase 2
- The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
- Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular LymphomaNot yet recruitingNCT06474481Phase 2
- Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular LymphomaRecruitingNCT06471738Phase 2
- Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLEnrolling by invitationNCT06468943Phase 2
- Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL PatientsRecruitingNCT06463691Phase 2
- A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSLRecruitingNCT06445257Not applicable
- This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaNot yet recruitingNCT06427213Phase 2
- A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCLRecruitingNCT06375733Phase 1/2
- MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLNot yet recruitingNCT06367374Phase 2
- Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasRecruitingNCT06350318Phase 2
- A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell LymphomaRecruitingNCT06341556Phase 2
- A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-TRecruitingNCT06167785Phase 2
- A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell LymphomaRecruitingNCT06136351Phase 2
- Zanubrutinib and Tafasitamab in Mantle Cell LymphomaRecruitingNCT06029309Phase 1/2
- The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaRecruitingNCT06021977Phase 2
- A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's MacroglobulinemiaRecruitingNCT05979948Phase 2
- Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05940051Phase 2
- Zanubrutinib in the Treatment of Relapsed/Refractory wAIHARecruitingNCT05922839Phase 2
- Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMRecruitingNCT05914662Phase 2
- Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCTRecruitingNCT05896007Phase 2
- Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk FactorsNot yet recruitingNCT05887726Phase 2
- Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's SyndromeRecruitingNCT05873712Phase 2
- Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) LymphomasRecruitingNCT05681195Phase 2
- Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell LymphomaRecruitingNCT05635162Phase 2
- Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial RemissionNot yet recruitingNCT05596097Phase 2
- Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell LymphomaRecruitingNCT05504603Phase 2
- The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.RecruitingNCT05428670Phase 2
- A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular LymphomaRecruitingNCT05389293Phase 2
- Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune ThrombocytopeniaNot yet recruitingNCT05369377Phase 2
- The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune ThrombocytopeniaNot yet recruitingNCT05369364Phase 2
- Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell LymphomaRecruitingNCT05348213Phase 2
- ZR-CHOP in DLBCL With Specific Gene AbnormalityRecruitingNCT05290337Phase 2
- ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCLRecruitingNCT05290090Phase 2
- A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune ThrombocytopeniaRecruitingNCT05214391Phase 2
- Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary ThrombocytopeniaRecruitingNCT05199909Phase 2
- Zanubrutinib and Venetoclax in CLL (ZANU-VEN)RecruitingNCT05168930Phase 2
- Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System LymphomaRecruitingNCT05117814Not applicable
- Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS LymphomaRecruitingNCT04938297Phase 2
- Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLRecruitingNCT04835870Phase 2
- Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor ZanubrutinibCompletedNCT05068440Phase 2Results posted
- Zanubrutinib in Patients With IgG4-Related DiseaseCompletedNCT04602598Phase 2Results posted
- Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell MalignanciesCompletedNCT04551963Phase 1Results posted
- The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy MalesCompletedNCT04470908Phase 1Results posted
- Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04436107Phase 1Results posted
- Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized ParticipantsCompletedNCT04382586Phase 2Results posted
- Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabCompletedNCT04282018Phase 1/2Results posted
- Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone LymphomaCompletedNCT03846427Phase 2Results posted
- A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic LeukemiaCompletedNCT03734016Phase 3Results posted
- BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)CompletedNCT03520920Phase 2Results posted
- A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLActive, not recruitingNCT03336333Phase 3Results posted
- Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)CompletedNCT03332173Phase 2Results posted
- A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular LymphomaCompletedNCT03332017Phase 2Results posted
- Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT03206970Phase 2Results posted
- Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03206918Phase 2Results posted
- A Study to Investigate Zanubrutinib in Chinese Participants With B-cell LymphomaCompletedNCT03189524Phase 1Results posted
- Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell LymphomaCompletedNCT03145064Phase 2Results posted
- Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell MalignanciesCompletedNCT02795182Phase 1Results posted
- BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid MalignanciesCompletedNCT02569476Phase 1Results posted
- Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid MalignanciesCompletedNCT02343120Phase 1/2Results posted